Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months

被引：0
|
作者：
Byrne, Robert A. [3 ,4 ,10 ]
Valgimigli, Marco [4 ,11 ,12 ]
Bhatt, Deepak L. [13 ]
Coughlan, J. J. [3 ]
Gibson, C. Michael [14 ]
Rossello, Xavier [5 ,6 ,7 ,8 ]
Gorog, Diana A. [15 ]
Ibanez, Borja [7 ,8 ,9 ]
James, Stefan [16 ]
Landi, Antonio [10 ,11 ]
Steg, P. Gabriel [17 ]
Stone, Gregg W. [18 ]
Andreotti, Felicita [1 ,2 ]
机构：
[1] Fdn Policlin Univ Gemelli IRCCS, Cardiovasc Sci Dept, Largo Gemelli 8, I-00168 Rome, Italy
[2] Catholic Univ, Med Sch, CardioThorac Dept, Rome, Italy
[3] Cardiovasc Res Inst, Mater Private Network, 73 Eccles St, Dublin D07 WKW8, Ireland
[4] RCSI Univ Med & Hlth Sci, Sch Pharm & Biomol Sci, Dublin, Ireland
[5] Hosp Univ Son Espases, Cardioctr Ticino Inst, CH-6900 Palma, Switzerland
[6] Univ Italian Switzerland, Fac Biomed Sci, Palma, Switzerland
[7] Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain
[8] CIBERCV, Madrid, Spain
[9] IIS Fdn Jimenez Diaz, Dept Cardiol, Madrid, Spain
[10] Ente Osped Cantonale EOC, Cardioctr Ticino Inst, CH-6900 Lugano, Switzerland
[11] Univ Italian Switzerland, Fac Biomed Sci, Lugano, Switzerland
[12] Univ Bern, Bern, Switzerland
[13] Mt Sinai Fuster Heart Hosp, Icahn Sch Med Mt Sinai, New York, NY USA
[14] Harvard Med Sch, Boston, MA USA
[15] Imperial Coll, Natl Heart & Lung Inst, Fac Med, London, England
[16] Uppsala Univ, Uppsala Clin Res Ctr, Dept Med Sci, Uppsala, Sweden
[17] Paris Cite Univ, Bichat Hosp, AP HP, Paris, France
[18] Zena & Michael A Wiener Cardiovasc Inst, Icahn Sch Med Mt Sinai, New York, NY USA
来源：
EUROPEAN HEART JOURNAL | 2025年
关键词：
Acute coronary syndrome; Antithrombotic therapy; Dual antiplatelet therapy; Duration; ANTITHROMBOTIC THERAPY; CLOPIDOGREL; TICAGRELOR; IMPLANTATION; STRATEGIES; PRASUGREL; OUTCOMES;
D O I：
10.1093/eurheartj/ehaf070
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：14
相关论文
共 50 条
  • [41] Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing Percutaneous Coronary Intervention: a the GReek AntiPlatelet registry (GRAPE) substudy
    Hamilos, M.
    Stilianos, S. P. Petousis
    Ioanna, I. X. Xanthopoulou
    Virginia, V. M. Mplani
    Spyros, S. D. Deftereos
    John, J. G. Goudevenos
    Panos, P. V. Vardas
    Dimitrios, D. A. Alexopoulos
    EUROPEAN HEART JOURNAL, 2016, 37 : 1382 - 1382
  • [42] Duration of Dual Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Diabetes: A Systematic Review and Meta-analysis
    Apostolos, Anastasios
    Travlos, Christofer
    Tsioulos, Georgios
    Chlorogiannis, Dimitrios-David
    Karanasos, Antonios
    Papafaklis, Michail
    Alexopoulos, Dimitrios
    Toutouzas, Konstantinos
    Davlouros, Periklis
    Tsigkas, Grigorios
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2024, 83 (01) : 64 - 72
  • [43] Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry
    Harjai, K. J.
    Shenoy, C.
    Orshaw, P.
    Boura, J.
    HEART, 2009, 95 (19) : 1579 - 1586
  • [44] Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Fioretti, Vincenzo
    Sperandeo, Luca
    Gerardi, Donato
    Di Fazio, Aldo
    Stabile, Eugenio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [45] Direct medical cost associated with antiplatelet nonpersistence in acute coronary syndrome patients after percutaneous coronary intervention
    Kristin, Erna
    Dinarti, Lucia Kris
    Febrinasari, Ratih Puspita
    Yasmina, Alfi
    Jaya, Sudi Indra
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 288 - 288
  • [46] Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
    Lee, Seung Hwa
    Yang, Jeong Hoon
    Choi, Seung-Hyuk
    Park, Taek Kyu
    Jang, Woo Jin
    Song, Young Bin
    Hahn, Joo-Yong
    Choi, Jin-Ho
    Gwon, Hyeon-Cheol
    PLOS ONE, 2017, 12 (05):
  • [47] Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk
    Spinler, Sarah A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (15) : S7 - S17
  • [48] DUAL ANTIPLATELET THERAPY DE-ESCALATION MODALITIES IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Greco, Antonio
    Laudani, Claudio
    Occhipinti, Giovanni
    Scalia, Lorenzo
    Agnello, Federica
    Legnazzi, Marco
    Mauro, Maria Sara
    Rochira, Carla
    Buccheri, Sergio
    Mehran, Roxana
    James, Stefan
    Angiolillo, Dominick
    Capodanno, Davide
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
  • [49] Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
    Wang, Yehua
    Cavallari, Larisa H.
    Brown, Joshua D.
    Thomas, Cameron D.
    Winterstein, Almut G.
    JAMA NETWORK OPEN, 2023, 6 (04) : e238585
  • [50] Contemporary Antiplatelet Treatment in Acute Coronary Syndrome Patients with Impaired Renal Function Undergoing Percutaneous Coronary Intervention
    Davlouros, Periklis
    Xanthopoulou, Ioanna
    Goudevenos, John
    Hamilos, Michalis
    Vavuranakis, Emmanouil
    Sitafidis, George
    Kanakakis, Ioannis
    Deftereos, Spyridon
    Alexopoulos, Dimitrios
    CARDIOLOGY, 2017, 138 (03) : 186 - 194
12345